Letter to the Editor
When platelets are activated, they increase in size and change from a quiescent disc to a swollen sphere. Large platelets are more reactive and likely aggregate more than small ones. 1 Mean platelet volume (MPV), an indicator of platelet size and activation, has been shown to predict ischemic stroke, myocardial infarction, and overall vascular mortality. 2, 3 The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) study showed that ezetimibe added to statin therapy further decreases low density lipoprotein cholesterol (LDL-C) levels and prevented acute coronary syndromes. 4 In this study, we investigated the lowering effect of LDL-C and MPV changes in patients who are on statin-ezetimibe combination therapy and those who receive statin monotherapy. Patients with acute ischemic cerebral infarctions (n = 120) were divided into those who were on statin therapy (n= 60) and those on statin plus ezetimibe (n= 60). The statin group received either atorvastatin (20 mg; n = 13) or rosuvastatin (10 mg; n = 48). The statin plus ezetimibe group received ezetimibe (10 mg) on top of the same dose of statin (atorvastatin plus ezetimibe, n = 14; rosuvastatin plus ezetimibe, n = 47). Student's ttests showed that MPV and serum LDL-C levels were more significantly decreased (MPV: P< 0.001; LDL-C: P= 0.017) by statin plus ezetimibe combination therapy (MPV: from 7.39 ± 1.04 [5.8-9 .2] to 6.04 ± 0.58 [4.9-7. Statin has pleiotrophic effects and modulates platelet function by direct interactions with platelet membranes or by influencing signaling pathways, irrespective of the cholesterol-lowering effects. Aydin et al. reported that high doses of statin decrease MPV and LDL-C levels in patients with diabetes, but the changes in LDL-C and MPV did not correlate. 5 Nevertheless, Marek et al.
reported that MPV was correlated with small dense LDL-C. 6 The possible mechanisms through which small dense LDL-C increases MPV include easier oxidation and glycation, which enhances the mobilization of arachidonic acid from phospholipids and decreases membrane fluidity. However, small dense-LDL-C measurements are time consuming and expensive in real life. In general, statin and ezetimibe induce reductions in all LDL-C subclasses. Ezetimibe blocks the critical mediator of cholesterol absorption, the Niemann-Pick C1-like 1 (NPC1L1) protein, on gastrointestinal tract epithelial cells as well as in hepatocytes, which causes them to absorb more LDL-C from the circulation and lower the circulating cholesterol level.
The previously proposed mechanisms of hypercholesterolemia in platelet activation are increased thromboxane A2 biosynthesis, inhibition of the platelet Na+/H+ antiport, decreased platelet endogenous nitric oxide production, and diminished endothelial nitric oxide synthase (eNOS) protein expression. 7 In addition, platelet activation by high LDL-C through platelet signaling pathways has been reported. 8 The effects of ezetimibe monotherapy on the LDL subclass profile are controversial. Kasper et al. reported that ezetimibe increases small dense LDL-C in healthy men. 9 In contrast, other studies have reported that ezetimibe decreases all LDL-C subclasses, including small dense LDL-C. 10 Our results showed that MPV and LDL-C levels were more significantly decreased by statin and ezetimibe combination therapy than statin monotherapy and that their levels are closely correlated. Our data suggest that the lowering of LDL-C may causally related with MPV changes and support the "Lower LDL-C, better outcome" findings of the IMPROVE-IT study. 4 
